Bret J. Stancil

Partner

Silicon Valley
bret.stancil@lw.com
+1.650.463.3087

PRACTICES

  • Mergers & Acquisitions
  • Private Equity

INDUSTRIES

  • Healthcare & Life Sciences
  • Retail & Consumer Products
  • Technology

BAR QUALIFICATIONS

  • California
  • New York

EDUCATION

  • JD, University of Pennsylvania Law School, 2013
    magna cum laude
  • BS in Biology, University of Nevada, 2010

LANGUAGES SPOKEN

  • English

PROFILE

Bret Stancil regularly advises leading corporate and private equity clients on significant M&A transactions and related corporate matters.

Bret represents private and public companies and private equity firms across a wide range of industries, including technology and software, life sciences, internet and digital media, and retail and consumer products.

He advises clients on a full spectrum of general corporate matters and strategic transactions, including:

  • Public and private mergers
  • Acquisitions
  • Dispositions
  • Carve-outs
  • Growth equity investments
  • Leveraged buyouts

Leveraging the resources of the firm’s global platform, Bret delivers pragmatic and solution-oriented advice that allows clients to quickly execute on significant transactions and achieve their business objectives effectively and efficiently.

Before joining Latham, Bret practiced at a leading international law firm in New York.

EXPERIENCE

Bret’s experience includes advising:

Technology

  • SGH in its acquisition of Stratus Technologies
  • Intuit in its:
    • US$12 billion acquisition of Mailchimp, a customer engagement and marketing platform
    • US$7.1 billion acquisition of Credit Karma, a leading consumer technology platform
    • US$340 million acquisition of TSheets, a provider of cloud-based time-tracking technology
    • Acquisition of TradeGecko, a SaaS company developing online inventory and order management software
  • Lyft in its:
    • Acquisition of Motivate, a bike-share operator
    • Acquisition of Blue Vision Labs, a developer of augmented reality software for self-driving cars
  • Discord in various strategic transactions
  • Meta in various strategic acquisitions
  • Vroom in its US$120 million acquisition of CarStory
  • Avago Technologies in its US$37 billion acquisition of Broadcom, a provider of semiconductor solutions for wired and wireless communications
  • Hightower in its strategic combination with VTS
  • Intermolecular in its sale to Merck
  • Mattson Technology in its US$300 million sale to Beijing E-Town Capital
  • Pericom Semiconductor in its US$413 million sale to Diodes and successful defense against hostile bidder Montage Technology
  • STRATIM Systems, a provider of mobility and fleet management software, in its sale to KAR Auction Services
  • Xcerra, a designer, manufacturer, and marketer of test equipment for the semiconductor industry, in its US$796 million sale to Cohu

Private Equity

  • Silver Lake on numerous transactions, including its lead participation, along with DigitalBridge, in Vantage Data Centers’ US$6.4 billion equity investment round
  • GreyLion Partners on numerous transactions, including its:
    • Sale of MTL Holdings to Carlisle Companies
    • Investment in SkinSpirit
    • Investment in Delphon Industries
    • Investment in Black Bear Diner
  • Dragoneer Investment Group on various transactions
  • Arcline Investment Management in its acquisition of a majority stake in Electric Power Systems International and North American Substation Services
  • GTCR in its US$5.1 billion acquisition of AssuredPartners, a leading US insurance brokerage, from Apax Partners
  • PWP Growth Equity, a private equity fund managed by Perella Weinberg Partners, in connection with various acquisition and investment transactions

Life Sciences

  • Amneal Pharmaceuticals in its US$6.4 billion merger with Impax Laboratories, a bioequivalent pharmaceutical products company
  • Bioventus in its equity investment and acquisition option structure with CartiHeal
  • Mirna Therapeutics in its reverse merger with Synlogic, a biotechnology company providing proprietary microbial engineering platforms for therapeutic microbe development
  • Nivalis Therapeutics in its reverse merger with Alpine Immune Sciences, a developer of protein-based immunotherapies targeting the immune synapse to treat cancer, autoimmune disorders, and other diseases
  • Relypsa in its US$1.53 billion sale to Galenica AG